Adaptive Biotechnologies Corp

ADPT

15.770USD

-0.700-4.25%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Adaptive Biotechnologies Corp's Score

Industry at a Glance

Industry Ranking

34 / 392

Overall Ranking

134 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Adaptive Biotechnologies Corp Highlights

StrengthsRisks

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 62.66% year-on-year.

Undervalued

The company’s latest PE is -40.21, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 148.20M shares, increasing 0.03% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 11.26M shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

20.500

Target Price

+24.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Adaptive Biotechnologies Corp is 7.94, ranking 69 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 71.68M, representing a year-over-year increase of 51.04%, while its net profit experienced a year-over-year increase of 59.70%.

Score

Industry at a Glance

Previous score

7.94

Change

0



Financials

5.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.36

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Adaptive Biotechnologies Corp is 6.95, ranking 197 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -40.21, which is -96.09% below the recent high of -1.57 and -4.44% above the recent low of -42.00.

Score

Industry at a Glance

Previous score

6.95

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Adaptive Biotechnologies Corp is 8.50, ranking 105 out of 392 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 21.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Adaptive Biotechnologies Corp is 6.82, ranking 162 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 18.69 and the support level at 13.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.98

Change

-0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Adaptive Biotechnologies Corp is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 104.17%, representing a quarter-over-quarter decrease of 0.83%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 29.99M shares, representing 19.65% of shares outstanding, with 0.49% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Viking Global Investors LP

Star Investors

29.99M

--

The Vanguard Group, Inc.

Star Investors

11.25M

-0.04%

BlackRock Institutional Trust Company, N.A.

10.91M

-1.40%

Columbia Threadneedle Investments (US)

5.78M

+145.35%

Geode Capital Management, L.L.C.

3.40M

+5.78%

ARK Investment Management LLC

Star Investors

3.17M

-21.18%

Aristotle Atlantic Partners, LLC

3.13M

+8.59%

State Street Investment Management (US)

3.08M

+1.72%

Driehaus Capital Management, LLC

3.02M

+24.61%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Adaptive Biotechnologies Corp is 4.86, ranking 66 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Adaptive Biotechnologies Corp

ADPT

7.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment